Irinotecan therapy and molecular targets in colorectal cancer: A systemic review

World Journal of Gastroenterology

Volumn 15, Issue 29, 2009, Pages 3597-3602

  Weekes, Jessica ^a   Lam, Alfred King Yin ^b   Sebesan, Sabe ^c   Ho, Yik Hong ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Colorectal cancer; Irinotecan; Molecular; P53; Vascular endothelial growth factor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; GELATINASE B; IRINOTECAN; NK 012; OXALIPLATIN; PROTEIN P53; SEMAXANIB; STAT1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DENSITY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG POTENTIATION; DYSPNEA; EDEMA; ENDOTHELIUM CELL; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; MORBIDITY; NAUSEA; NEUTROPENIA; NULL CELL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349581033     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3597     Document Type: Review

References (39)

1. Stewart BW, Kleihues P, eds. World Cancer Report. IARC non-serial publication. Lyon: IARC, 2003
2. Washington MK. Colorectal carcinoma: selected issues in pathologic examination and staging and determination of prognostic factors. Arch Pathol Lab Med 2008; 132: 1600-1607
3. Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 108-120
4. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005; 28: 417-433
5. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418
6. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412
7. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-795
8. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009; 14: 597-606
9. Lam AK, Ong K, Ho YH. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorectal Dis 2008; 23: 587-594
10. Lam AK, Ong K, Giv MJ, Ho YH. p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 2008; 40: 580-585
11. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994; 86: 681-687
12. Flamini G, Curigliano G, Ratto C, Astone A, Ferretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, Cittadini A. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 1996; 32A: 802-806
13. Diez M, Pollan M, Müguerza JM, Gaspar MJ, Duce AM, Alvarez MJ, Ratia T, Herñandez P, Ruiz A, Granell J. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma. Cancer 2000; 88: 35-41
14. Lanza G Jr, Maestri I, Dubini A, Gafa R, Santini A, Ferretti S, Cavazzini L. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 1996; 105: 604-612
15. Adrover E, Maestro ML, Sanz-Casla MT, del Barco V, Cerdán J, Fernández C, Balibrea JL. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer 1999; 81: 122-126
16. Royston D, Jackson DG. Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 2009; 217: 608-619
17. Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 2005; 11: 8063-8069
18. Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008; 144: 934-940; discussion 940-941
19. Yu XM, Lo CY, Lam AK, Leung P, Luk JM. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008; 247: 483-489
20. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410
21. Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, Bucana CD, Rikita T, Tahara E, Fidler IJ. Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 2000; 157: 1523-1535
22. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832
23. Kondo Y, Arii S, Furutani M, Isigami S, Mori A, Onodera H, Chiba T, Imamura M. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000; 88: 1820-1827
24. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallböhmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006; 12: 29-33
25. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 183-194
26. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ieranò C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, Scala S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12: 2795-2803
27. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-1384
28. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006; 19: 1317-1323
29. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11: 2053-2062
30. Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci USA 2000; 97: 8490-8494
31. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 1996; 16: 1126-1137
32. McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 8951-8960
33. Abal M, Bras-Goncalves R, Judde JG, Fsihi H, De Cremoux P, Louvard D, Magdelenat H, Robine S, Poupon MF. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004; 23: 1737-1744
34. Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK. Targeted therapy in rectal cancer. Oncology (Williston Park) 2007; 21: 1055-1065; discussion 1065, 1070, 1075 passim
35. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006; 66: 10048-10056
36. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008; 98: 1619-1629
37. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765: 178-188
38. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-12490
39. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999; 3: 147-158